PCA3 Molecular Urine Test as a Predictor of Repeat Prostate Biopsy Outcome in Men with Previous Negative Biopsies: A Prospective Multicenter Clinical Study
Abstract
Purpose:
We evaluated the clinical usefulness of the PROGENSA® PCA3 Assay for predicting repeat prostate biopsy outcome.
Materials and Methods:
Men with at least 1 prior negative prostate biopsy who were scheduled for repeat prostate biopsy based on best clinical judgment were enrolled at 14 centers. Whole blood and post-digital rectal examination urine samples were collected before extended template transrectal biopsy with 12 or more cores. Urinary PCA3 scores and biopsy outcomes were assessed by logistic regression analysis, which also included age, race, serum prostate specific antigen, clinical stage, family history of prostate cancer and the number of previous negative biopsy sessions.
Results:
A total of 466 men were included in study and prostate cancer was identified in 21.9%. A PCA3 score cutoff of 25 yielded 77.5% sensitivity, 57.1% specificity, and negative and positive predictive values of 90% and 33.6%, respectively. On multivariable logistic regression men with a PCA3 score of less than 25 were 4.56 times as likely to have a negative repeat biopsy as men with a score of 25 or greater. PCA3 score significantly increased the predictive accuracy of the logistic regression model. At 90% sensitivity adding the PCA3 score to the model increased specificity, and positive and negative predictive values by 22.6%, 6.4% and 7.1%, respectively, relative to the model without the PCA3 score.
Conclusions:
The PCA3 score supplements serum prostate specific antigen and other clinical information to provide more accurate prediction of repeat biopsy outcome. Thus, it provides clinicians and patients with independent, clinically useful information to make more informed repeat biopsy decisions.
References
- 1 : Cancer Facts and Figures. Atlanta: American Cancer Society2012. Google Scholar
- 2 : Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med2012; 157: 120. Google Scholar
- 3 : Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol1994; 151: 1283. Abstract, Google Scholar
- 4 : Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int2008; 102: 1524. Google Scholar
- 5 : Screening and prostate-cancer mortality in a randomized European study. N Engl J Med2009; 360: 1320. Google Scholar
- 6 : Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?. J Urol2001; 166: 1679. Link, Google Scholar
- 7 : Serial biopsy results in prostate cancer screening study. J Urol2002; 167: 2435. Link, Google Scholar
- 8 : Repeat prostate biopsy and the incremental risk of clinically insignificant prostate cancer. Urology2011; 77: 548. Google Scholar
- 9 : Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology2002; 60: 826. Google Scholar
- 10 : Current status of transrectal ultrasound-guided prostate biopsy in the diagnosis of prostate cancer. Clin Radiol2006; 61: 142. Google Scholar
- 11 : Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol2010; 183: 963. Link, Google Scholar
- 12 : DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res1999; 59: 5975. Google Scholar
- 13 : DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res2002; 62: 2695. Google Scholar
- 14 : DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol2003; 44: 8. Google Scholar
- 15 : PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology2007; 69: 532. Google Scholar
- 16 : PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol2008; 179: 1587. Link, Google Scholar
- 17 : Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol2008; 54: 1081. Google Scholar
- 18 : Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol2010; 58: 475. Google Scholar
- 19 : PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. J Urol2010; 184: 1947. Link, Google Scholar
- 20 : PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol2008; 179: 1804. Link, Google Scholar
- 21 : Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur Urol2011; 59: 96. Google Scholar
- 22 : Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol2011; 59: 422. Google Scholar
- 23 : Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer. Prostate Cancer Prostatic Dis2012; 15: 100. Google Scholar
- 24 : APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem2006; 52: 1089. Google Scholar
- 25 : Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics1988; 44: 837. Google Scholar
- 26 : PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol2008; 180: 1975. Link, Google Scholar
- 27 : Urinary PCA3 score predicts prostate cancer multifocality. J Urol2011; 185: 1234. Link, Google Scholar
- 28 : Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate2008; 68: 1215. Google Scholar
- 29 : Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate2010; 70: 10. Google Scholar
